$EVMN

Moss Gregory S. sold $325K of EVMN

Moss Gregory S. (Chief Business & Legal Officer) sold 14,223 shares of Evommune, Inc. (EVMN) at $22.83 ($0.32M total) on 2026-05-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Moss Gregory S.
Published Jun 2, 2026, 12:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 2, 2026, 12:02 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$EVMN
Neutral
medium confidence
Mentioned
$EVMN
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EVMNNeutralLow
01

Why it matters

The disclosure provides a datapoint on insider liquidity/positioning, but the pre-arranged 10b5-1 plan reduces interpretability as a new negative signal.

02

Market read

Traders may treat this as low-signal sentiment noise rather than a fundamental catalyst.

03

What to watch

The filing doesn’t reveal whether the officer’s remaining holdings are being reduced via multiple planned trades; also consider whether other insiders/funds filed contemporaneous Form 4/13D/13G activity.

Relevance 6/10Novelty 2/10Timing: Filed June 1; sale executed May 28 (10b5-1 open-market).

Background

This is an SEC Form 4 insider transaction disclosure for Evommune, Inc. (EVMN).

Company-level read

Ticker impact

$EVMNNeutralMedium confidence
Context

Evommune officer sold 14,223 shares in an open-market transaction for ~$324.7K, disclosed via SEC Form 4 with a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect is more sentiment/positioning than fundamentals.

Evidence & confidence

Form 4 shows a scheduled 10b5-1 sale rather than discretionary selling, and the filing provides no new operating or deal catalyst.

Market effects

No clear sector read-through; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can still coincide with weaker near-term expectations; monitor for additional sales or changes in trading patterns.

Key entities

  • Evommune, Inc.

    Subject of the insider transaction disclosure (EVMN).

  • Moss Gregory S.

    Chief Business & Legal Officer who sold shares under a 10b5-1 plan.

Related articles

$EVMNMed

Evommune, Inc. (EVMN): Results of Operations and Financial Condition

Evommune, Inc. (EVMN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 evmn-ex99_1.htm EX-99.1 EX-99.1 Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights ‑ Company to announce EVO756 atopic dermatitis (AD) Phase 2b top-line data in September 2026 ‑ EVO756 migraine prophylaxis Phase 2b dose-ranging trial